WO2007145239A1 - Anti-fatigue agent containing amino acid composition - Google Patents

Anti-fatigue agent containing amino acid composition Download PDF

Info

Publication number
WO2007145239A1
WO2007145239A1 PCT/JP2007/061879 JP2007061879W WO2007145239A1 WO 2007145239 A1 WO2007145239 A1 WO 2007145239A1 JP 2007061879 W JP2007061879 W JP 2007061879W WO 2007145239 A1 WO2007145239 A1 WO 2007145239A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatigue
weight
parts
amino acid
acid composition
Prior art date
Application number
PCT/JP2007/061879
Other languages
French (fr)
Japanese (ja)
Inventor
Masato Saito
Hiroyuki Arita
Hiroshi Tsuchita
Original Assignee
Meiji Dairies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corporation filed Critical Meiji Dairies Corporation
Priority to JP2008521230A priority Critical patent/JP5775657B2/en
Publication of WO2007145239A1 publication Critical patent/WO2007145239A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Anti-fatigue agent containing amino acid composition
  • the present invention relates to a fatigue inhibitor containing an amino acid composition having a specific type of amino acid strength.
  • Fatigue is broadly classified into acute fatigue and chronic fatigue when classified from the onset, and the former occurs in units of several minutes and several hours and often recovers after a relatively short rest. The latter is a force that recovers for several days without recovery when acute fatigue accumulates, or weekly for long periods. There is.
  • these methods may include administration of certain drugs or supplements.
  • drug administration diagnosis and prescribing by a doctor are necessary, which is complicated.
  • dietary supplements as a supplement are simple and easy to incorporate into daily life.
  • research and development and product development have been promoted, and supplement factories are steadily expanding.
  • fatigue recovery supplements such as citrate, vitamins, and coenzyme Q10 are also sold at convenience stores.
  • the effect of recovering the fatigue of each of the above-mentioned muscle fatigue and nerve fatigue has not been clarified, and there is still no clear method for satisfying both of them in practice. Not obtained.
  • Patent Document 1 discloses an amino acid composition that quickly recovers mental fatigue such as fatigue of muscles themselves and fatigue associated therewith.
  • Non-Patent Document 1 discloses that amino acids such as proline, glycine, and alanine are significantly consumed and decreased in humans who have been subjected to a long-term bicycle load.
  • Non-Patent Document 2 discusses changes in the concentration of plasma components with and without carbohydrate supplementation during exercise. This document shows that plasma concentrations of glycine, allan, lysine, threonine, and histidine are decreased, and in particular, the decrease rate of histidine is large.
  • Non-Patent Document 3 also discloses the results of studies on changes in the concentrations of various plasma components in a system with and without feeding during exercise. Here, it is disclosed that the concentration reduction rate of tributophane is particularly large!
  • Patent Document 1 Japanese Patent No. 2518692
  • Patent Document 2 JP-A-8-198748
  • Patent Document 3 Reissue 2002Z034257
  • Non-Patent Document 1 G. Ahlborg et al., The Journal of Clinical Investigat ion, 53rd, April 1974, ⁇ .1080-1090
  • Non-Patent Document 2 T. L. Bazare et al. ( ⁇ ⁇ . Bazzare et al), Journal of the American College of Nutrition, 1992, Vol. 11, No. 5, p. 501-511
  • Non-Patent Document 3 A. H. Forslund et al., Am. J. Physiol Endocrinol Metab., 2000, 278, p.857-867
  • these conventional amino acid yarns and composites are mainly intended to improve athletic ability, and have not yet been sufficiently examined in terms of anti-fatigue effect and fatigue prevention.
  • technologies that are particularly effective for recovery from fatigue and prevention but in any case, studies on the effects of preventing muscle fatigue and nerve fatigue are insufficient, and it is difficult to say that they have been solved.
  • these conventional amino acid compositions have to supply various kinds and a large amount of amino acids as a composition, which inevitably has a problem of high cost.
  • the present inventors have found that an amino acid composition having an unprecedented composition and quantity ratio can provide an effect of preventing fatigue that has been insufficient in the past. Was completed.
  • an object of the present invention is to provide an anti-fatigue agent containing an amino acid composition having a specific type of specific amount of amino acid.
  • the present invention provides an anti-fatigue agent comprising an amino acid composition having the following amino acid strength:
  • an anti-fatigue agent containing the following amino acids in addition to the amino acid yarn composition having the above-described structure is preferable:
  • an anti-fatigue agent containing the following amino acids in addition to the amino acid yarn composition having the above structure is preferable:
  • the present invention relates to the anti-fatigue agent described above, which simultaneously prevents both muscle fatigue and nerve fatigue.
  • the present invention also relates to the anti-fatigue agent as described above, wherein muscle fatigue is evaluated by measuring the amount of behavior, and nerve fatigue is evaluated by measuring blood biomarkers.
  • the present invention is that the behavioral amount of the non-administered group is 100 or more when the behavioral amount of the non-administration group is 100), and the evaluation by the blood biomarker measurement When the measured concentration of the non-administered group is 100, the measured concentration (relative value) of the administered group is 96 or less, and the anti-fatigue agent is evaluated to have an effect of preventing muscle fatigue and nerve fatigue.
  • the composition used for the anti-fatigue agent of the present invention is an amino acid composition having a composition and quantity ratio that has not been conventionally used. Thereby, it is possible to obtain a high effect for preventing fatigue which has been insufficient in the past. That is, for the first time according to the present invention, both actual muscle fatigue and nerve fatigue can be prevented simultaneously.
  • the amount of amino acids is less than that of conventional amino acid compositions, and high! ⁇ Because it is possible to obtain the effect of preventing fatigue, the number of raw material types required for preparation is reduced, and the effect is high both industrially and economically.
  • a high fatigue prevention effect can be obtained with a smaller amount of amino acid than in the conventional amino acid composition, the effect is high both industrially and economically.
  • the amount of each amino acid used is small, and when this is prepared so as to be suitable for beverages, etc., a low-capacity beverage can be measured as a beverage. In particular, it becomes effective as a portable beverage such as a speed link.
  • amino acid composition contained in the anti-fatigue agent of the present invention those containing the following amino acids in the following quantitative ratios are preferred: 30 to 200 parts by weight of proline;
  • the amino acid composition having the above composition preferably further contains the following amino acids.
  • amino acid yarn and composition further contain the following amino acids.
  • the amino acid composition contained in the fatigue inhibitor of the present invention preferably contains the following amino acids in the following quantitative ratios.
  • Glycine 75- L 10 parts by weight
  • an anti-fatigue agent containing an amino acid composition consisting of these nine amino acids is preferred.
  • the amino acid yarn composition contained in the anti-fatigue agent of the present invention preferably contains the following amino acids in the following quantitative ratios.
  • Glycine 75- L 10 parts by weight
  • Tribfan fan 25 to 65 parts by weight of Tribfan fan
  • an anti-fatigue agent comprising an amino acid composition having only 9 types of amino acid power is preferred.
  • the amino acid composition contained in the anti-fatigue agent of the present invention the following amino acid is preferably used in the following quantitative ratio. Is included.
  • tyrosine is more preferably 35 to 55 parts by weight.
  • the anti-fatigue agent of the present invention has an anti-fatigue effect on both muscular fatigue and nerve fatigue by two types of evaluation systems: measurement of the amount of behavior during fatigue and measurement of one blood biomarker during fatigue. It is evaluated.
  • Evaluation by the behavioral amount measurement is performed by, for example, applying exercise load to the two groups of the administration group (administration of amino acid composition) and the non-administration group (control group) with a treadmill or the like.
  • the behavioral amount was measured, and the relative behavioral amount of the administration group was calculated when the behavioral amount of the non-administration group was taken as 100.
  • the amount of activity in the administration group exceeds 100, preferably 110 or more, more preferably 120 or more, particularly preferably 190 or more, the administered amino acid composition is effective in preventing muscle fatigue. It can be evaluated that it has.
  • the action amount (relative value) of the administration group is higher in the effect of preventing muscle fatigue as the value is larger.
  • blood biomarker measurement is performed by applying exercise load to the two groups, an administration group (administration of amino acid string and adult) and a non-administration group (control group) using a treadmill or the like. Blood was collected after a lapse of a certain period of time, and the concentrations of blood marker in the two groups were measured, and the relative measured concentration of the administration group was calculated when the measurement concentration of the non-administration group was taken as 100.
  • the measured concentration (relative value) of the administration group is less than 100 If it is 96 or less, it can be evaluated as having an effect of preventing nerve fatigue.
  • the measured concentration (relative value) of the administration group when the measured concentration (relative value) of the administration group is preferably 95 or less, more preferably 80 or less, it can be evaluated as having an effect of preventing nerve fatigue.
  • IFN-y when the measured concentration (relative value) of the administration group is preferably 60 or less, more preferably 45 or less, it can be evaluated as having an effect of preventing nerve fatigue.
  • IL-10 when used as an index, it can be evaluated that it has an effect of preventing nerve fatigue when the measured concentration of the administration group is preferably 70 or less, more preferably 50 or less.
  • the measured concentration (relative value) in the administration group is more effective in preventing nerve fatigue as the value is smaller. Can be evaluated as high.
  • Mechionin preferably 0.3 to 0.7 mol 0/0, more preferably 0.4 to 0.6 moles 0 / 0
  • Asuparagin acid preferably 0.1 to 0.3 mole 0/0
  • taurine preferably 3 mole 0/0 or less
  • phosphoric acid ethanolamine preferably not more than 2 mol%
  • cystine preferably 0.5 mol% or less
  • J8- Aranin favored properly below 1 mol%)
  • Amino acid preferably not more than 0.5 mol%), ol - Chin or ethanol ⁇ Min (preferably 3 moles 0 / 0 or less), ammonia (preferably 2 mole 0/0 or less), 1-methylhistidine (preferably not more than 3 mol%), 3-methylhistidine (preferably may contain 1 mol% or less). It is particularly preferred that the amino acid in the amino acid composition used in the present invention is an L-amino acid.
  • Each amino acid used in the present invention is preferably a single product having a high purity.
  • These amino acids can also be used in the form of their physiologically acceptable salts.
  • the above-mentioned commercially available amino acids may be mixed in the above-mentioned predetermined proportions. When used as a solution, it may be dissolved in distilled water. Usually, it is powdered and mixed uniformly to form a composition, which can be dissolved in distilled water at the time of use.
  • the temperature at which the composition of the present invention is produced and stored is not particularly limited, but it is preferably produced and stored at room temperature or lower.
  • Examples of the dosage form of the anti-fatigue agent of the present invention include oral administration such as tablets, coated tablets, capsules, granules, powders, solutions, syrups, and emulsions. These various preparations are prepared by adding the excipient, binder, disintegrant, lubricant, coloring agent, flavoring agent, solubilizing agent, suspending agent, coating agent, etc. to the amino acid composition according to the present invention according to a conventional method. It can be formulated using known adjuvants that can be usually used in the field of pharmaceutical formulation.
  • the amino acid composition that is the main component of the anti-fatigue agent of the present invention is extremely safe and can be set in a wide range of dosages. In general, it can be appropriately set in consideration of various factors such as the administration route, the age, weight, and symptoms of animals to be administered including humans.
  • the present invention is not limited to this, but preferably, lg to 8 gZkgZday is appropriate as an active ingredient. It is.
  • composition of the present invention can be administered in advance when it is desired to prevent fatigue and used as an anti-fatigue agent, and can also be administered afterwards when fatigue is felt and used as a fatigue recovery agent.
  • a 3 to 6.0 wt% solution 100 to 500 ml per day may be administered 1 to 3 times.
  • the anti-fatigue agent of the present invention can be administered by any deviation from oral administration or parenteral administration (intramuscular, subcutaneous, intravenous, suppository, transdermal, etc.).
  • the anti-fatigue agent of the present invention can also be used as a special-purpose food such as a food for specified health use containing the composition, and the anti-fatigue agent of the present invention is contained in a food composition to provide a nutritional function food. By directly ingesting it as a functional food such as the above, it is possible to easily obtain an effect of preventing fatigue.
  • various foods and drinks milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, disease
  • the anti-fatigue agent of the present invention may be added in its composition to foods for consumers, foods such as infant formula, foods such as infant formula, nutritional foods, and the like. Furthermore, it can be used in accordance with conventional methods for ordinary food yarns and adult products such as other foods and mixed with food ingredients.
  • the state of the food or drink usually used for example, solid (powder, granule, etc.), paste, liquid or suspension may be used.
  • the other components are not particularly limited, but for example, foods and drinks included in the food composition include water, proteins, carbohydrates, lipids, and vitamins. Minerals, organic acids, organic bases, fruit juices, flavors and the like can be used as ingredients.
  • proteins include whole milk powder, skim milk powder, partially skim milk powder, force zein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, j8-lacto Globulin, ⁇ -ratatoanolbumin, ratatofurin, soy protein, egg protein, meat protein, etc. And various milk-derived components.
  • lipids include animal oils such as lard and fish oil, fractionated oils, hydrogenated oil, transesterified oil, and the like; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples thereof include vegetable oils such as hydrogenated oil and ester exchange oil.
  • vitamins for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin!
  • vitamin Q vitamin Q
  • niacin nicotinic acid
  • pantothenic acid biotin, inositol
  • minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like.
  • organic acid include malic acid, citrate, lactic acid, tartaric acid, and the like.
  • mice Male, 8 weeks old, C57BLZ6N, rearing environment: 23 ⁇ 3 ° C, 12 hours light / dark cycle
  • mice Male, 8 weeks old, C57BLZ6N, rearing environment: 23 ⁇ 3 ° C, 12 hours light / dark cycle
  • mice were allocated so that the weight of each group was as uniform as possible, and each group had 3 to 4 samples. It was divided into a group (Example) and a control group (Comparative example). They were forcibly orally administered with the fatigue inhibitor of the present invention or physiological saline as a control without fasting.
  • One hour after administration, exercise load was applied by a treadmill test (25 mZmin for 60 minutes).
  • the dose was 500 mgZkg body weight in terms of amino acid (5% suspension was administered at 10 ⁇ LZg body weight).
  • the amino acid composition of the anti-fatigue agent of the present invention administered here is shown in Table 1 (the amino acid composition values are expressed in parts by weight).
  • Examples 1 to 6 of the present invention increases in the concentrations of cortisol, IFN-y, and IL-10 are remarkably suppressed. Since these compounds increase in concentration in proportion to the increase in fatigue, they can be evaluated as alternative indicators of mental fatigue. That is, in Examples 1 to 6 of the present invention, also in the effect of preventing mental fatigue. It turns out that it has a high effect. Further, it can be seen that this tendency appears more remarkably in Examples 5 and 6.
  • the anti-fatigue agent comprising the amino acid yarn according to the present invention can provide a high anti-fatigue effect that simultaneously prevents both muscular fatigue and mental fatigue.
  • it is a composition consisting of fewer types of amino acids, so that the number of raw material types required for preparation is reduced and industrial production is reduced. In addition, it has an excellent economic effect. Therefore, the industrial utility value is high.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

It is intended to provide an anti-fatigue agent capable of preventing both muscle fatigue and nerve fatigue simultaneously. According to the invention, both muscle fatigue and nerve fatigue can be simultaneously prevented with the anti-fatigue agent containing an amino acid composition comprising specific types and specific amounts of amino acids. With regard to preferred amino acid types and amount ratios, it is an amino acid composition containing 30 to 200 parts by weight of proline, 60 to 140 parts by weight of glycine, 25 to 260 parts by weight of alanine, 40 to 130 parts by weight of lysine, 20 to 75 parts by weight of tryptophan, and 15 to 40 parts by weight of histidine. Further, it preferably contains 35 to 65 parts by weight of threonine, 15 to 65 parts by weight of tyrosine, and 25 to 45 parts by weight of arginine, and further, it preferably contains 30 to 55 parts by weight of valine, 35 to 60 parts by weight of leucine, and 25 to 45 parts by weight of isoleucine.

Description

明 細 書  Specification
アミノ酸組成物を含有する疲労防止剤  Anti-fatigue agent containing amino acid composition
技術分野  Technical field
[0001] 本発明は特定種のアミノ酸力 なるアミノ酸組成物を含有する疲労防止剤に関する 背景技術  TECHNICAL FIELD [0001] The present invention relates to a fatigue inhibitor containing an amino acid composition having a specific type of amino acid strength.
[0002] 現代社会に生きる人間にとって「疲労」という現象は、既に単純には無視できない 状況となりつつある。近年の調査結果によると、全国民の 60%近くが疲労を感じてお り、そのうち 40%弱の人々が 6ヶ月以上継続する疲労を感じていると回答している。こ れを就労人口に換算すると 3000万人近くの労働者が継続した疲労感を伴ったまま で業務に従事していることになる。また、重篤な慢性疲労の場合には日常生活にも支 障を来す場合もある。さらに、これらの疲労によって引き起こされる経済的損失は、回 復措置に係る費用も含めると、数千億円力 一兆円規模となると推測されている。  [0002] For human beings living in modern society, the phenomenon of “fatigue” is already becoming a situation that cannot be simply ignored. According to recent survey results, nearly 60% of all citizens feel tired, and nearly 40% of them feel that they have been tired for more than 6 months. Converting this to the working population, nearly 30 million workers are engaged in work with continued fatigue. Severe chronic fatigue can also interfere with daily life. Furthermore, the economic losses caused by these fatigues are estimated to be in the order of several hundred billion yen and one trillion yen, including the cost of recovery measures.
[0003] 疲労は、発現から分類した場合には急性疲労と慢性疲労とに大別され、前者は数 分力 数時間の単位で発生し、比較的短時間の休息で回復する場合が多い。後者 は急性疲労が蓄積された場合に、回復せずに数日、長い場合には週間単位で回復 するレベルのものである力 上記のように長期に渡る場合には 6ヶ月以上継続するこ とちある。  [0003] Fatigue is broadly classified into acute fatigue and chronic fatigue when classified from the onset, and the former occurs in units of several minutes and several hours and often recovers after a relatively short rest. The latter is a force that recovers for several days without recovery when acute fatigue accumulates, or weekly for long periods. There is.
[0004] また、疲労が生じる部位力も分類した場合には、肉体疲労と精神 (神経)疲労とに大 別される。但し、これらの疲労については筋肉疲労と神経疲労とで分類できるもので はあるが、そのストレスから見た場合には、実際には常にお互いが複雑に関連して生 じている。したがって、上記の単純な分類では対処方法は一義的には見いだせず、 この点についての知見が得られれば、効果的な疲労回復措置を構築することにもつ ながる。  [0004] Furthermore, when the part force that causes fatigue is also classified, it is roughly classified into physical fatigue and mental (nerve) fatigue. However, although these types of fatigue can be classified into muscle fatigue and nerve fatigue, in terms of the stress, in reality, they are always associated with each other in a complicated manner. Therefore, in the above simple classification, the coping method cannot be found uniquely, and if knowledge about this point is obtained, it will lead to the construction of effective fatigue recovery measures.
[0005] 疲労防止や回復の方法としては、入浴などの簡易的なストレス解消方法から、薬剤 投与まで含めた治療方法が種々検討されている。これらの方法は、上記した筋肉疲 労と神経疲労とのそれぞれの疲労を回復することを目的としているが、実際にはその 双方を同時に満足するような方法は未だ得られて 、な 、。 [0005] As a method for preventing and recovering from fatigue, various treatment methods including simple stress relieving methods such as bathing to drug administration have been studied. These methods are aimed at recovering the above-mentioned fatigue of muscle fatigue and nerve fatigue. We still have no way to satisfy both at the same time.
[0006] また、これらの方法においてはある種の薬剤又はサプリメントなどの投与を含んでい る場合がある。薬剤投与の場合には医者などによる診断や処方の対応が必要である ことから煩雑である。一方、サプリメントとしての食餌による対応方法は、簡便であり日 常生活に取り入れやすいこともあり、近年その研究開発 ·商品開発が進められており 、サプリメント巿場は拡大の一途をたどっている。例えば、クェン酸、ビタミン、コェン ザィム Q10を初めとする疲労回復用サプリメントはコンビ-エンスストア等でも巿販さ れている。しかし、これらのサプリメントにおいても、上記した筋肉疲労と神経疲労との それぞれの疲労を回復する効果については明らかにされておらず、実際にはその双 方を同時に満足するような明確な方法は未だ得られていない。  [0006] In addition, these methods may include administration of certain drugs or supplements. In the case of drug administration, diagnosis and prescribing by a doctor are necessary, which is complicated. On the other hand, dietary supplements as a supplement are simple and easy to incorporate into daily life. In recent years, research and development and product development have been promoted, and supplement factories are steadily expanding. For example, fatigue recovery supplements such as citrate, vitamins, and coenzyme Q10 are also sold at convenience stores. However, even in these supplements, the effect of recovering the fatigue of each of the above-mentioned muscle fatigue and nerve fatigue has not been clarified, and there is still no clear method for satisfying both of them in practice. Not obtained.
[0007] 一方、主に運動能力向上の目的で注目を集め商品名「VAAM」（明治乳業株式会 社製）として知られて ヽるスズメバチの幼虫が分泌するだ液中に含まれる複数のァミノ 酸組成物については、疲労回復にも効果があるとされており（例えば特許文献 1)、さ らにこの技術力も派生した種々のアミノ酸組成物につ 、ても開発が進められて 、る。 例えば特許文献 2には、筋肉自体の疲労ならびにそれに伴う倦怠感などの精神的疲 労を速やかに回復するアミノ酸組成物が開示されている。  [0007] On the other hand, a plurality of amino acids contained in the saliva secreted by the hornet larvae, known as the product name “VAAM” (manufactured by Meiji Dairies Co., Ltd.), which attracted attention mainly for the purpose of improving athletic ability The acid composition is said to be effective for recovery from fatigue (for example, Patent Document 1), and various amino acid compositions derived from this technical capability are being developed. For example, Patent Document 2 discloses an amino acid composition that quickly recovers mental fatigue such as fatigue of muscles themselves and fatigue associated therewith.
[0008] また、 BCAAとして知られて!/、るパリン、ロイシン、イソロイシンにつ!、ては、これらに も運動能力向上としての用途以外に、中枢神経系の疲労 (脳性疲労)予防若しくは 脳疲労回復効果があるとして、これを用いた中枢神経系用疲労予防 Z回復剤が提 供されている (特許文献 3)。  [0008] Also known as BCAA! /, Ruparin, leucine, and isoleucine! In addition to their use for improving motor ability, they also prevent central nervous system fatigue (cerebral fatigue) or the brain. As a fatigue recovery effect, a central nervous system fatigue preventive Z recovery agent using the same has been provided (Patent Document 3).
[0009] 一方、いくつかの疲労に関する研究の結果から、疲労に伴いある種のアミノ酸の血 中濃度の低下や特定組織への取り込みが行われることが知られている。例えば、非 特許文献 1には自転車による長時間負荷を与えたヒトにおいて、プロリン、グリシン、 ァラニンなどのアミノ酸が有意に消費され低下することが開示されている。  [0009] On the other hand, it has been known from the results of several studies on fatigue that blood concentrations of certain amino acids are lowered and taken into specific tissues with fatigue. For example, Non-Patent Document 1 discloses that amino acids such as proline, glycine, and alanine are significantly consumed and decreased in humans who have been subjected to a long-term bicycle load.
[0010] また非特許文献 2には運動時における炭水化物の補給の有無条件での血漿中成 分についての濃度変化について検討が行われている。この文献ではグリシン、ァラ- ン、リジン、スレオニン、ヒスチジンの血漿中濃度低下がみられ、特にヒスチジンの低 下率が大き 、ことが示されて 、る。 [0011] 非特許文献 3にも運動時における給餌有無の系における各種血漿中成分の濃度 変化についての研究結果が開示されている。ここでは特にトリブトファンの濃度低下 率が大き!/ヽことが開示されて!ヽる。 [0010] In addition, Non-Patent Document 2 discusses changes in the concentration of plasma components with and without carbohydrate supplementation during exercise. This document shows that plasma concentrations of glycine, allan, lysine, threonine, and histidine are decreased, and in particular, the decrease rate of histidine is large. [0011] Non-Patent Document 3 also discloses the results of studies on changes in the concentrations of various plasma components in a system with and without feeding during exercise. Here, it is disclosed that the concentration reduction rate of tributophane is particularly large!
[0012] その量が低下したそれぞれのアミノ酸につ 、ての運動や疲労現象との因果関係は 未だ明確にはされて ヽな 、が、エネルギー代謝サイクルにお 、てこれらのアミノ酸が 何らかの関わりがあり消費されているものと推測される。したがって、これらの濃度低 下が見られるアミノ酸を補充することで疲労回復することは容易に想像される。しかし 、肉体疲労、精神疲労後にこれらを単純に補充することでも容易には疲労回復する ことは無ぐまたこれらを事前に投与したとしても、疲労回復効果が得られるという事 実は未だ知られていない。  [0012] For each amino acid whose amount has been reduced, the causal relationship between exercise and fatigue has not yet been clarified, but in the energy metabolism cycle, these amino acids have some relationship. Presumed to be consumed. Therefore, it is easily imagined that fatigue recovery can be achieved by supplementing these amino acids with a decreased concentration. However, simply replenishing them after physical fatigue or mental fatigue does not easily recover from fatigue, and even if they are administered in advance, the fact that a fatigue recovery effect can be obtained is not yet known. .
[0013] 特許文献 1 :特許第 2518692号公報  Patent Document 1: Japanese Patent No. 2518692
特許文献 2：特開平 8 - 198748号公報  Patent Document 2: JP-A-8-198748
特許文献 3：再表 2002Z034257号公報  Patent Document 3: Reissue 2002Z034257
非特許文献 1 : G.ァーボルグ等（G.Ahlborg et al) , The Journal of Clinical Investigat ion,第 53卷, 1974年 4月号 ,ρ.1080- 1090  Non-Patent Document 1: G. Ahlborg et al., The Journal of Clinical Investigat ion, 53rd, April 1974, ρ.1080-1090
非特許文献 2 :T. L.バザーレ等（Τ丄. Bazzare et al) , Journal of the American Colle ge of Nutrition, 1992年,第 11卷,第 5号 ,p.501- 511  Non-Patent Document 2: T. L. Bazare et al. (Τ 丄. Bazzare et al), Journal of the American College of Nutrition, 1992, Vol. 11, No. 5, p. 501-511
非特許文献 3 : A. H.フォースランド等（A.H.Forslund et al) , Am.J.Physiol Endocrin ol Metab.,2000年,第 278卷 ,p.857- 867  Non-Patent Document 3: A. H. Forslund et al., Am. J. Physiol Endocrinol Metab., 2000, 278, p.857-867
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0014] 上述のように、これら従来のアミノ酸糸且成物は、運動能力の向上が主たる目的であ り、抗疲労効果、疲労防止という観点力もの検討については未だ不十分であった。ま た、特に疲労回復や予防についての効果を謳う技術もあるが、いずれも筋肉疲労と 神経疲労との防止効果についての検討は不十分なものであり、未だ解決されたとは 言い難い。さらに、これら従来のアミノ酸組成物は多種かつ多量のアミノ酸を組成物 として供給しなければならず、必然的に高コストなものとなってしまう問題点が潜在し ている。 [0015] 本発明者等は、鋭意研究の結果、従来には無い組成と量比にてアミノ酸組成物を 構成することで、従来不十分であった疲労防止効果を得ることを見出し、本発明を完 成した。 [0014] As described above, these conventional amino acid yarns and composites are mainly intended to improve athletic ability, and have not yet been sufficiently examined in terms of anti-fatigue effect and fatigue prevention. In addition, there are technologies that are particularly effective for recovery from fatigue and prevention, but in any case, studies on the effects of preventing muscle fatigue and nerve fatigue are insufficient, and it is difficult to say that they have been solved. Further, these conventional amino acid compositions have to supply various kinds and a large amount of amino acids as a composition, which inevitably has a problem of high cost. As a result of diligent research, the present inventors have found that an amino acid composition having an unprecedented composition and quantity ratio can provide an effect of preventing fatigue that has been insufficient in the past. Was completed.
従って、本発明の目的は、特定種類の特定量のアミノ酸力 なるアミノ酸組成物を 含有する疲労防止剤を提供することにある。  Accordingly, an object of the present invention is to provide an anti-fatigue agent containing an amino acid composition having a specific type of specific amount of amino acid.
課題を解決するための手段  Means for solving the problem
[0016] すなわち、本発明は以下のアミノ酸力 なるアミノ酸組成物を含む疲労防止剤を提 供する： [0016] That is, the present invention provides an anti-fatigue agent comprising an amino acid composition having the following amino acid strength:
プロリン 30〜200重量部；  30 to 200 parts by weight of proline;
グリシン 60〜 140重量咅；  Glycine 60-140 wt.
ァラニン 25〜260重量言  Alanin 25-260 weight
リジン 40〜130重量咅  Lysine 40-130 wt
トリプトファン 20〜75重量部；  Tryptophan 20-75 parts by weight;
ヒスチジン 15〜40重量部。  Histidine 15-40 parts by weight.
[0017] また、上記構成のアミノ酸糸且成物にさらに、以下のアミノ酸を含有する疲労防止剤 が好ましい：  [0017] Further, an anti-fatigue agent containing the following amino acids in addition to the amino acid yarn composition having the above-described structure is preferable:
スレオ-ン 35〜65重量部；  35-65 parts by weight of threon;
チロシン 15〜65重量部；  Tyrosine 15-65 parts by weight;
アルギニン 25〜45重量部。  Arginine 25-45 parts by weight.
[0018] また、上記構成のアミノ酸糸且成物にさらに、以下のアミノ酸を含有する疲労防止剤 が好ましい：  [0018] Further, an anti-fatigue agent containing the following amino acids in addition to the amino acid yarn composition having the above structure is preferable:
ノ リン 30〜55重量部；  Norin 30-55 parts by weight;
ロイシン 35〜60重量部；  35-60 parts by weight of leucine;
イソロイシン 25〜45重量部。  25 to 45 parts by weight of isoleucine.
[0019] さらに本発明は、筋肉疲労および神経疲労の双方を同時に防止する、前記の疲労 防止剤に関する。 [0019] Furthermore, the present invention relates to the anti-fatigue agent described above, which simultaneously prevents both muscle fatigue and nerve fatigue.
また本発明は、筋肉疲労が行動量測定によって評価されるものであり、神経疲労が 血中バイオマーカー測定によって評価されるものである、前記の疲労防止剤に関す る。 The present invention also relates to the anti-fatigue agent as described above, wherein muscle fatigue is evaluated by measuring the amount of behavior, and nerve fatigue is evaluated by measuring blood biomarkers. The
さらに本発明は、行動量測定による評価において、非投与群の行動量を 100とした 場合に投与群の行動量湘対値)が 110以上であり、かつ、血中バイオマーカー測定 による評価において、非投与群の測定濃度を 100とした場合に投与群の測定濃度（ 相対値)が 96以下であり、筋肉疲労および神経疲労の防止効果を有すると評価され る、前記の疲労防止剤に関する。  Furthermore, in the evaluation by the behavioral amount measurement, the present invention is that the behavioral amount of the non-administered group is 100 or more when the behavioral amount of the non-administration group is 100), and the evaluation by the blood biomarker measurement When the measured concentration of the non-administered group is 100, the measured concentration (relative value) of the administered group is 96 or less, and the anti-fatigue agent is evaluated to have an effect of preventing muscle fatigue and nerve fatigue.
発明の効果  The invention's effect
[0020] 本発明の疲労防止剤に用いられる組成物は、従来には無い組成と量比によるアミ ノ酸組成物である。これにより、従来不十分であった疲労防止について高い効果を得 ることが出来る。すなわち本発明により初めて、実際の筋肉疲労と神経疲労との双方 を同時に防止することが出来る。  [0020] The composition used for the anti-fatigue agent of the present invention is an amino acid composition having a composition and quantity ratio that has not been conventionally used. Thereby, it is possible to obtain a high effect for preventing fatigue which has been insufficient in the past. That is, for the first time according to the present invention, both actual muscle fatigue and nerve fatigue can be prevented simultaneously.
[0021] 本発明においては、その評価系として疲労時の行動量測定と疲労時の血中バイオ マーカー測定との 2種の評価系を特に用いて、それぞれを筋肉疲労と精神疲労の指 標とした。その結果、本発明のアミノ酸組成物に関して特に両評価系における顕著な 疲労防止効果を得ることが出来た。  [0021] In the present invention, two types of evaluation systems are specifically used as the evaluation system, namely, an action amount measurement during fatigue and a blood biomarker measurement during fatigue, and these are used as indicators of muscle fatigue and mental fatigue, respectively. did. As a result, it was possible to obtain a remarkable anti-fatigue effect in both evaluation systems with respect to the amino acid composition of the present invention.
[0022] また本発明によれば、従来のアミノ酸組成物よりも少な 、種類のアミノ酸で高！ヽ疲 労防止効果を得ることが出来るために、調製に必要な原材料種が減り、工業的にも 経済的にも高い効果を奏する。  [0022] Further, according to the present invention, the amount of amino acids is less than that of conventional amino acid compositions, and high!ヽ Because it is possible to obtain the effect of preventing fatigue, the number of raw material types required for preparation is reduced, and the effect is high both industrially and economically.
[0023] さらに、従来のアミノ酸組成物よりも少ない量のアミノ酸により高い疲労防止効果が 得られることからも、工業的にも経済的にも高い効果を奏する。また、従来同等の効 果を得るように調製した場合には、それぞれのアミノ酸の使用量が少なぐこれを飲料 等に適するように調製した場合には飲料として低容量ィ匕を計ることができ、特にスポ ーッドリンクなど携帯用飲料として有効なものとなる。  [0023] Further, since a high fatigue prevention effect can be obtained with a smaller amount of amino acid than in the conventional amino acid composition, the effect is high both industrially and economically. In addition, when prepared so as to obtain the same effect as before, the amount of each amino acid used is small, and when this is prepared so as to be suitable for beverages, etc., a low-capacity beverage can be measured as a beverage. In particular, it becomes effective as a portable beverage such as a speed link.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0024] 以下、本発明を詳細に説明するが、本発明は以下に述べる個々の形態には限定さ れない。 [0024] The present invention will be described in detail below, but the present invention is not limited to the individual forms described below.
[0025] 本発明の疲労防止剤に含まれるアミノ酸組成物としては、下記のアミノ酸を下記の 量比で含むものが好ま U、。 プロリン 30〜200重量部； [0025] As the amino acid composition contained in the anti-fatigue agent of the present invention, those containing the following amino acids in the following quantitative ratios are preferred: 30 to 200 parts by weight of proline;
グリシン 60〜： 140重量部；  Glycine 60 ~: 140 parts by weight;
ァラニン 25〜260重量部；  Alanine 25-260 parts by weight;
リジン 40〜130重量部；  40-130 parts by weight of lysine;
トリブトファン 20〜75重量部；  20 to 75 parts by weight of tribute fan;
ヒスチジン 15〜40重量咅  Histidine 15-40 weight
[0026] 上記組成のアミノ酸組成物には、下記のアミノ酸をさらに含有することが好ましい。  [0026] The amino acid composition having the above composition preferably further contains the following amino acids.
スレオニン 35〜65重量部；  35-65 parts by weight of threonine;
チロシン 15〜65重量部；  Tyrosine 15-65 parts by weight;
アルギニン 25〜45重量部。  Arginine 25-45 parts by weight.
[0027] また、上記糸且成のアミノ酸糸且成物には、下記のアミノ酸をさらに含有することが好ま しい。  [0027] Furthermore, it is preferable that the above-described amino acid yarn and composition further contain the following amino acids.
ノ リン 30〜55重量部；  Norin 30-55 parts by weight;
ロイシン 35〜60重量部；  35-60 parts by weight of leucine;
イソロイシン 25〜45重量部。  25 to 45 parts by weight of isoleucine.
[0028] 本発明の疲労防止剤に含まれるアミノ酸組成物としては、好ましくは下記のアミノ酸 を下記の量比で含むものである。 [0028] The amino acid composition contained in the fatigue inhibitor of the present invention preferably contains the following amino acids in the following quantitative ratios.
プロリン 40〜150重量部；  40-150 parts by weight of proline;
グリシン 75〜： L 10重量部；  Glycine 75-: L 10 parts by weight;
ァラニン 30〜220重量言  Alanin 30-220 weight
リジン 55〜95重量部；  Lysine 55-95 parts by weight;
トリプトファン 25〜65重量部；  Tryptophan 25-65 parts by weight;
ヒスチジン 20〜35重量部；  20 to 35 parts by weight of histidine;
スレオニン 35〜65重量部；  35-65 parts by weight of threonine;
チロシン 15〜65重量部；  Tyrosine 15-65 parts by weight;
アルギニン 25〜45重量部。  Arginine 25-45 parts by weight.
また、この 9種のみのアミノ酸からなるアミノ酸組成物を含む疲労防止剤が好まし ヽ さらに、本発明の疲労防止剤に含まれるアミノ酸糸且成物としては、好ましくは下記の アミノ酸を下記の量比で含むものである。 In addition, an anti-fatigue agent containing an amino acid composition consisting of these nine amino acids is preferred. Furthermore, the amino acid yarn composition contained in the anti-fatigue agent of the present invention preferably contains the following amino acids in the following quantitative ratios.
プロリン 40〜150重量部；  40-150 parts by weight of proline;
グリシン 75〜： L 10重量部；  Glycine 75-: L 10 parts by weight;
ァラニン 30〜220重量部；  Alanine 30-220 parts by weight;
リジン 55〜95重量部；  Lysine 55-95 parts by weight;
トリブトファン 25〜65重量部；  25 to 65 parts by weight of Tribfan fan;
ヒスチジン 20〜35重量部；  20 to 35 parts by weight of histidine;
バリン 30〜55重量部；  30-55 parts by weight of valine;
ロイシン 35〜60重量部；  35-60 parts by weight of leucine;
25〜45重量部。  25 to 45 parts by weight.
また、この 9種のみのアミノ酸力 なるアミノ酸組成物を含む疲労防止剤が好ましい また、本発明の疲労防止剤に含まれるアミノ酸組成物としては、好ましくは下記のァ ノ酸を下記の量比で含むものである。  Further, an anti-fatigue agent comprising an amino acid composition having only 9 types of amino acid power is preferred. Also, as the amino acid composition contained in the anti-fatigue agent of the present invention, the following amino acid is preferably used in the following quantitative ratio. Is included.
プロリン 40〜120重量部；  40-120 parts by weight of proline;
グリシン 60〜85重量部；  60-85 parts by weight of glycine;
ァラニン 25〜170重量部；  Alanine 25-170 parts by weight;
リジン 40〜75重量部；  40-75 parts by weight of lysine;
トリブトファン 20〜50重量部；  20 to 50 parts by weight of tribute fan;
ヒスチジン 20〜30重量部；  20-30 parts by weight of histidine;
スレ才ニン 35〜55重量部；  Threaded Nin 35-55 parts by weight;
チロシン 15〜55重量部；  Tyrosine 15-55 parts by weight;
ァ /レギニン 25〜40重量部；  A / legginin 25-40 parts by weight;
バリン 30〜40重量部；  30-40 parts by weight of valine;
ロイシン 35〜50重量部；  35-50 parts by weight of leucine;
25〜40重量部。  25 to 40 parts by weight.
本発明においては、特に好ましくはこれら 12種のみのアミノ酸力もなるアミノ酸糸且成 物を含む疲労防止剤である。 In the present invention, it is particularly preferable that only these 12 kinds of amino acid strengths are formed. It is an anti-fatigue agent containing things.
なお、上記構成のアミノ酸組成物においては、チロシンはさらに好ましくは 35〜55 重量部である。  In the amino acid composition having the above structure, tyrosine is more preferably 35 to 55 parts by weight.
[0031] また本発明の疲労防止剤は、疲労時の行動量測定と疲労時の血中バイオマーカ 一測定との 2種の評価系により、筋肉疲労および神経疲労の双方において疲労防止 効果があると評価される。  [0031] Further, the anti-fatigue agent of the present invention has an anti-fatigue effect on both muscular fatigue and nerve fatigue by two types of evaluation systems: measurement of the amount of behavior during fatigue and measurement of one blood biomarker during fatigue. It is evaluated.
[0032] 行動量測定による評価は、例えば、投与群 (アミノ酸組成物を投与)と非投与群 (コ ントロール群）との 2つの群に対し、トレッドミルなどによって運動負荷を与え、 2群の 行動量をそれぞれ測定し、非投与群の行動量を 100とした場合の投与群の相対的 な行動量を算出して行った。投与群の行動量湘対値)が、 100を越えた場合、好ま しくは 110以上、さらに好ましくは 120以上、とくに好ましくは 190以上の場合、投与し たアミノ酸組成物は、筋肉疲労の防止効果を有すると評価できる。なお、投与群の行 動量 (相対値)は、数値が大きいほど筋肉疲労の防止効果が高いと評価できる。  [0032] Evaluation by the behavioral amount measurement is performed by, for example, applying exercise load to the two groups of the administration group (administration of amino acid composition) and the non-administration group (control group) with a treadmill or the like. The behavioral amount was measured, and the relative behavioral amount of the administration group was calculated when the behavioral amount of the non-administration group was taken as 100. When the amount of activity in the administration group exceeds 100, preferably 110 or more, more preferably 120 or more, particularly preferably 190 or more, the administered amino acid composition is effective in preventing muscle fatigue. It can be evaluated that it has. In addition, it can be evaluated that the action amount (relative value) of the administration group is higher in the effect of preventing muscle fatigue as the value is larger.
[0033] 血中バイオマーカー測定による評価は、例えば、投与群 (アミノ酸糸且成物を投与）と 非投与群 (コントロール群）との 2つの群に対し、トレッドミルなどによって運動負荷を 与え、一定時間経過後に採血し、 2群の血中ノィォマーカーの濃度をそれぞれ測定 し、非投与群の測定濃度を 100とした場合の投与群の相対的な測定濃度を算出して 行った。任意の血中バイオマーカー（コルチゾール、インターフェロン γ (IFN- y )、インターロイキン 10 (IL— 10)を含む)を指標とした場合、投与群の測定濃度（ 相対値)が 100未満の場合、好ましくは 96以下の場合、神経疲労の防止効果を有す ると評価できる。  [0033] For example, blood biomarker measurement is performed by applying exercise load to the two groups, an administration group (administration of amino acid string and adult) and a non-administration group (control group) using a treadmill or the like. Blood was collected after a lapse of a certain period of time, and the concentrations of blood marker in the two groups were measured, and the relative measured concentration of the administration group was calculated when the measurement concentration of the non-administration group was taken as 100. When any blood biomarker (including cortisol, interferon γ (IFN-y), interleukin 10 (IL-10)) is used as an index, it is preferable if the measured concentration (relative value) of the administration group is less than 100 If it is 96 or less, it can be evaluated as having an effect of preventing nerve fatigue.
[0034] とくにコルチゾールを指標とした場合、投与群の測定濃度 (相対値)が、好ましくは 9 5以下、さらに好ましくは 80以下の場合、神経疲労の防止効果を有すると評価できる 。また IFN— yを指標とした場合、投与群の測定濃度 (相対値)が、好ましくは 60以 下、さらに好ましくは 45以下の場合、神経疲労の防止効果を有すると評価できる。さ らに IL— 10を指標とした場合、投与群の測定濃度湘対値)が、好ましくは 70以下、 さらに好ましくは 50以下の場合、神経疲労の防止効果を有すると評価できる。  [0034] In particular, when cortisol is used as an index, when the measured concentration (relative value) of the administration group is preferably 95 or less, more preferably 80 or less, it can be evaluated as having an effect of preventing nerve fatigue. Further, when IFN-y is used as an index, when the measured concentration (relative value) of the administration group is preferably 60 or less, more preferably 45 or less, it can be evaluated as having an effect of preventing nerve fatigue. Furthermore, when IL-10 is used as an index, it can be evaluated that it has an effect of preventing nerve fatigue when the measured concentration of the administration group is preferably 70 or less, more preferably 50 or less.
なお、投与群の測定濃度 (相対値)は、数値が小さいほど神経疲労の防止効果が 高いと評価できる。 The measured concentration (relative value) in the administration group is more effective in preventing nerve fatigue as the value is smaller. Can be evaluated as high.
[0035] 本発明の疲労防止剤には上記アミノ酸の他に、必要に応じて、メチォニン (好ましく は 0. 3〜0. 7モル0 /0、更に好ましくは 0. 4〜0. 6モル0 /0)、ァスパラギン酸（好ましく は 0. 1〜0. 3モル0 /0)、タウリン (好ましくは 3モル0 /0以下）、リン酸エタノールアミン（ 好ましくは 2モル％以下）、シスチン (好ましくは 0. 5モル％以下）、 j8—ァラニン (好ま しくは 1モル％以下）、 γ—ァミノ酪酸 (好ましくは 0. 5モル％以下）、オル-チン又は エタノールァミン (好ましくは 3モル0 /0以下）、アンモニア（好ましくは 2モル0 /0以下）、 1 メチルヒスチジン (好ましくは 3モル％以下）、 3 メチルヒスチジン (好ましくは 1モル %以下）を含んでいてもよい。本発明に使用するアミノ酸組成物中のアミノ酸は、特に L -アミノ酸であることが好ま U、。 [0035] In addition to the above amino acids in the anti-fatigue agent of the present invention, if necessary, Mechionin (preferably 0.3 to 0.7 mol 0/0, more preferably 0.4 to 0.6 moles 0 / 0), Asuparagin acid (preferably 0.1 to 0.3 mole 0/0), taurine (preferably 3 mole 0/0 or less), phosphoric acid ethanolamine (preferably not more than 2 mol%), cystine (preferably 0.5 mol% or less), J8- Aranin (favored properly below 1 mol%), .gamma. Amino acid (preferably not more than 0.5 mol%), ol - Chin or ethanol § Min (preferably 3 moles 0 / 0 or less), ammonia (preferably 2 mole 0/0 or less), 1-methylhistidine (preferably not more than 3 mol%), 3-methylhistidine (preferably may contain 1 mol% or less). It is particularly preferred that the amino acid in the amino acid composition used in the present invention is an L-amino acid.
[0036] 本発明で使用する各アミノ酸は、各々、単品で高純度のものが好ましい。例えば、「 食品添加物公定書」に規定する純度以上のアミノ酸を使用する。また、これらのァミノ 酸としては、その生理学的に許容し得る塩の形態のものも使用可能である。  [0036] Each amino acid used in the present invention is preferably a single product having a high purity. For example, use an amino acid with a purity higher than that specified in the “Food Additives Official Document”. These amino acids can also be used in the form of their physiologically acceptable salts.
[0037] 本発明のアミノ酸組成物を製造するにあたっては、市販の上記アミノ酸を上記の所 定割合で混合すれば良い。また溶液として使用する場合にはこれを、蒸留水に溶解 すれば良い。通常は粉末状で均一に混合して組成物としておき、使用時に蒸留水に 溶解すれば良い。本発明の組成物を製造、保存する温度は特に限定されないが、 室温以下で製造、保存することが好ましい。  [0037] In producing the amino acid composition of the present invention, the above-mentioned commercially available amino acids may be mixed in the above-mentioned predetermined proportions. When used as a solution, it may be dissolved in distilled water. Usually, it is powdered and mixed uniformly to form a composition, which can be dissolved in distilled water at the time of use. The temperature at which the composition of the present invention is produced and stored is not particularly limited, but it is preferably produced and stored at room temperature or lower.
[0038] 本発明の疲労防止剤の投与形態としては、例えば錠剤、被覆錠剤、カプセル剤、 顆粒剤、散剤、溶液、シロップ剤、乳液等による経口投与をあげることができる。これ らの各種製剤は、常法に従って本発明によるアミノ酸組成物に賦形剤、結合剤、崩 壊剤、滑沢剤、着色剤、矯味矯臭剤、溶解補助剤、懸濁剤、コーティング剤などの医 薬の製剤技術分野において通常使用しうる既知の補助剤を用いて製剤化することが できる。  [0038] Examples of the dosage form of the anti-fatigue agent of the present invention include oral administration such as tablets, coated tablets, capsules, granules, powders, solutions, syrups, and emulsions. These various preparations are prepared by adding the excipient, binder, disintegrant, lubricant, coloring agent, flavoring agent, solubilizing agent, suspending agent, coating agent, etc. to the amino acid composition according to the present invention according to a conventional method. It can be formulated using known adjuvants that can be usually used in the field of pharmaceutical formulation.
[0039] 本発明の疲労防止剤の主成分であるアミノ酸組成物は極めて安全性が高ぐ投与 量は広範に設定することができる。一般的には、投与経路、ヒトを含む投与対象動物 の年齢、体重、症状など、種々の要因を考慮して、適宜設定することができる。本発 明はこれに限定されないが、好ましくは、有効成分として lg〜8gZkgZdayが適当 である。 [0039] The amino acid composition that is the main component of the anti-fatigue agent of the present invention is extremely safe and can be set in a wide range of dosages. In general, it can be appropriately set in consideration of various factors such as the administration route, the age, weight, and symptoms of animals to be administered including humans. The present invention is not limited to this, but preferably, lg to 8 gZkgZday is appropriate as an active ingredient. It is.
[0040] 本発明の組成物は、疲労を防止したい時に事前に投与し疲労防止剤として使用す るばかりでなぐ疲労を感じた時に事後的に投与して疲労回復剤としても使用でき、 0 . 3〜6. 0重量％溶液として、 1日当たり 100〜500mlを 1〜3回投与すればよい。注 射剤としては 0. 3〜6. 0重量0 /0溶液として 1回あたり 100〜400ml、好ましくは 150 〜300mlを投与すればよ!、。 [0040] The composition of the present invention can be administered in advance when it is desired to prevent fatigue and used as an anti-fatigue agent, and can also be administered afterwards when fatigue is felt and used as a fatigue recovery agent. As a 3 to 6.0 wt% solution, 100 to 500 ml per day may be administered 1 to 3 times. Note: The Ysaye 0.3 to 6.0 weight 0/0 per as a solution 100~400ml, preferably it is administered the 150 ~300ml!,.
また本発明の疲労防止剤は、経口投与又は非経口投与 (筋肉内、皮下、静脈内、 坐薬、経皮等）の 、ずれでも投与できる。  In addition, the anti-fatigue agent of the present invention can be administered by any deviation from oral administration or parenteral administration (intramuscular, subcutaneous, intravenous, suppository, transdermal, etc.).
[0041] 本発明の疲労防止剤をその組成で含有する特定保健用食品等の特別用途食品と することも可能であり、また本発明の疲労防止剤は食品組成物に含ませ、栄養機能 食品等の機能性食品として直接摂取することにより、疲労防止効果を簡便に得ること ができる。  [0041] The anti-fatigue agent of the present invention can also be used as a special-purpose food such as a food for specified health use containing the composition, and the anti-fatigue agent of the present invention is contained in a food composition to provide a nutritional function food. By directly ingesting it as a functional food such as the above, it is possible to easily obtain an effect of preventing fatigue.
[0042] 具体的には、食品組成物として使用する場合には、各種飲食品（牛乳、清涼飲料、 発酵乳、ヨーグルト、チーズ、パン、ビスケット、クラッカー、ピッツァクラスト、調製粉乳 、流動食、病者用食品、幼児用粉乳等食品、授乳婦用粉乳等食品、栄養食品等）に 、本発明の疲労防止剤をその組成で添加し、これを摂取してもよい。さらに他の食品 な 、し食品成分と混合するなど、通常の食品糸且成物における常法にしたがって使用 できる。また、その性状についても、通常用いられる飲食品の状態、例えば、固体状（ 粉末、顆粒状その他）、ペースト状、液状ないし懸濁状のいずれでもよい。  [0042] Specifically, when used as a food composition, various foods and drinks (milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, disease The anti-fatigue agent of the present invention may be added in its composition to foods for consumers, foods such as infant formula, foods such as infant formula, nutritional foods, and the like. Furthermore, it can be used in accordance with conventional methods for ordinary food yarns and adult products such as other foods and mixed with food ingredients. In addition, the state of the food or drink usually used, for example, solid (powder, granule, etc.), paste, liquid or suspension may be used.
[0043] 食品組成物として使用する場合に、その他の成分についても特に限定はないが、 上記食品組成物に包含される、例えば飲食物には、水、タンパク質、糖質、脂質、ビ タミン類、ミネラル類、有機酸、有機塩基、果汁、フレーバー類等を成分として使用す ることができる。タンパク質としては、例えば全脂粉乳、脱脂粉乳、部分脱脂粉乳、力 ゼイン、ホエイ粉、ホエイタンパク質、ホエイタンパク質濃縮物、ホエイタンパク質分離 物、 α—カゼイン、 β—カゼイン、 κ—カゼイン、 j8—ラクトグロブリン、 α—ラタトァノレ ブミン、ラタトフヱリン、大豆タンパク質、鶏卵タンパク質、肉タンパク質等の動植物性 タンパク質、これら加水分解物;バター、乳清ミネラル、クリーム、ホエイ、非タンパク態 窒素、シアル酸、リン脂質、乳糖等の各種乳由来成分などが挙げられる。糖類、加工 澱粉 (デキストリンのほか、可溶性澱粉、プリティッシュスターチ、酸化澱粉、澱粉エス テル、澱粉エーテル等）、食物繊維などが挙げられる。脂質としては、例えば、ラード 、魚油等、これらの分別油、水素添加油、エステル交換油等の動物性油脂;パーム 油、サフラワー油、コーン油、ナタネ油、ヤシ油、これらの分別油、水素添加油、エス テル交換油等の植物性油脂などが挙げられる。ビタミン類としては、例えば、ビタミン A、カロチン類、ビタミン B群、ビタミン C、ビタミン D群、ビタミン E、ビタミン K群、ビタミ ン!3、ビタミン Q、ナイァシン、ニコチン酸、パントテン酸、ビォチン、イノシトール、コリ ン、葉酸などが挙げられ、ミネラル類としては、例えば、カルシウム、カリウム、マグネ シゥム、ナトリウム、銅、鉄、マンガン、亜鉛、セレンなどが挙げられる。有機酸としては 、例えば、リンゴ酸、クェン酸、乳酸、酒石酸などが挙げられる。これらの成分は、 2種 以上を組み合わせて使用することができ、合成品及び Z又はこれらを多く含む食品 を用いてもよい。 [0043] When used as a food composition, the other components are not particularly limited, but for example, foods and drinks included in the food composition include water, proteins, carbohydrates, lipids, and vitamins. Minerals, organic acids, organic bases, fruit juices, flavors and the like can be used as ingredients. Examples of proteins include whole milk powder, skim milk powder, partially skim milk powder, force zein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, j8-lacto Globulin, α-ratatoanolbumin, ratatofurin, soy protein, egg protein, meat protein, etc. And various milk-derived components. Sugars, processing Starch (in addition to dextrin, soluble starch, pre-taste starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber and the like. Examples of lipids include animal oils such as lard and fish oil, fractionated oils, hydrogenated oil, transesterified oil, and the like; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples thereof include vegetable oils such as hydrogenated oil and ester exchange oil. As vitamins, for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin! 3 , vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol And minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like. Examples of the organic acid include malic acid, citrate, lactic acid, tartaric acid, and the like. These components can be used in combination of two or more, and synthetic products and Z or foods containing a large amount thereof may be used.
実施例  Example
[0044] 以下、本発明の実施例を挙げて本発明についてさらに詳細に説明を行うが、本発 明は、これらの具体的な実施例に限定されない。  Hereinafter, the present invention will be described in more detail with reference to examples of the present invention, but the present invention is not limited to these specific examples.
[0045] マウス（雄、 8週齢、 C57BLZ6N、飼育環境 23 ± 3°Cで明暗 12時間サイクル）を 各群の体重が出来るだけ均一になるように割り付け、各群 3〜4匹力 なるサンプル 群 (実施例）とコントロール群 (比較例）とに分けた。これらは絶食させずに、本発明の 疲労防止剤又はコントロールとしての生理食塩水を強制経口投与した。投与後 1時 間後にトレッドミル試験（25mZminで 60分）による運動負荷を与えた。  [0045] Mice (male, 8 weeks old, C57BLZ6N, rearing environment: 23 ± 3 ° C, 12 hours light / dark cycle) were allocated so that the weight of each group was as uniform as possible, and each group had 3 to 4 samples. It was divided into a group (Example) and a control group (Comparative example). They were forcibly orally administered with the fatigue inhibitor of the present invention or physiological saline as a control without fasting. One hour after administration, exercise load was applied by a treadmill test (25 mZmin for 60 minutes).
[0046] なお、投与量はアミノ酸換算で 500mgZkg体重（5%懸濁液を 10 μ LZg体重に て投与)とした。ここで投与した本発明の疲労防止剤のアミノ酸組成を表 1に示す (ァ ミノ酸組成の数値は重量部にて示す)。  The dose was 500 mgZkg body weight in terms of amino acid (5% suspension was administered at 10 μLZg body weight). The amino acid composition of the anti-fatigue agent of the present invention administered here is shown in Table 1 (the amino acid composition values are expressed in parts by weight).
[0047] [試験 1] (疲労時の行動量測定）  [0047] [Test 1] (Measurement of behavior during fatigue)
トレッドミルによる運動負荷付与後に行動量測定を行った。なお行動量としては、赤 色ランプ点灯下で 30分間に行動した道のりの合計を測定した。コントロール群 (比較 例 1)を 100としたときのそれぞれの実施例における行動量を示した。すなわち、数値 が大き 、ほど筋肉疲労が少な 、ものと考えられる。 [0048] [試験 2] (疲労時の血中バイオマーカー測定） The amount of behavior was measured after the exercise load was applied by the treadmill. As the amount of action, we measured the total number of trips that acted for 30 minutes with the red lamp on. The amount of action in each example when the control group (Comparative Example 1) is 100 is shown. In other words, the larger the value, the less muscle fatigue. [0048] [Test 2] (Measurement of blood biomarkers during fatigue)
トレッドミル試験終了後一定時間経過後に採血し、血液中の免疫学的指標としてコ ルチゾール、インターフェロン一 γ (IFN— γ )、インターロイキン一 10 (IL— 10)を測 定した。コントロール群を 100としたときのそれぞれの実施例における濃度を示した。 すなわち、数値が小さいほど疲労感が低ぐ精神的疲労が少ないものと考えられる。  Blood was collected after a lapse of a certain time after completion of the treadmill test, and cortisol, interferon-1γ (IFN—γ), and interleukin-10 (IL-10) were measured as immunological indicators in the blood. The concentration in each example when the control group was 100 was shown. That is, it is considered that the smaller the numerical value, the lower the feeling of fatigue and the less the mental fatigue.
[0049] なお、これらの評価方法は、大阪市立大学医学部生化学'分子病態学講座井上正 康教授らが 2005年の日本生化学会で発表した方法 (演題：運動疲労における免疫 応答システムの性差解析、生化学、 2005年、第 77卷、 P.1056)に基づいて行った。  [0049] In addition, these evaluation methods are the methods presented by Prof. Masayasu Inoue et al., Department of Biochemistry, Molecular Chemistry, School of Medicine, Osaka City University (2005) (title: Gender difference analysis of immune response system in exercise fatigue) , Biochemistry, 2005, No. 77, P.1056).
[0050] [表 1]  [0050] [Table 1]
Figure imgf000013_0001
Figure imgf000013_0001
[0051] 本発明の実施例 1〜6の疲労防止剤においては、比較例 1と比べ、トレッドミルによ る運動負荷を与えた後にもさらに行動することが出来るという筋肉疲労の防止効果が 高いことが分かる。特に、実施例 5及び 6においては非常に高い運動後の行動量を 示している。 [0051] In the anti-fatigue agents of Examples 1 to 6 of the present invention, compared to Comparative Example 1, the effect of preventing muscular fatigue that can be further acted after applying an exercise load by a treadmill is high. I understand that. In particular, Examples 5 and 6 show a very high amount of action after exercise.
[0052] また、血中バイオマーカー測定による結果では、本発明の実施例 1〜6においては 、コルチゾール、 IFN - y、 IL— 10の濃度上昇が著しく抑制されている。これら化合 物は疲労感の上昇に比例して濃度が高くなるため、精神疲労の代替指標として評価 することができる。即ち、本発明の実施例 1〜6では精神疲労の防止効果においても 高い効果を有することが分かる。さらに、この傾向は実施例 5及び 6においてより顕著 に現れることが判る。 [0052] In addition, according to the results of blood biomarker measurement, in Examples 1 to 6 of the present invention, increases in the concentrations of cortisol, IFN-y, and IL-10 are remarkably suppressed. Since these compounds increase in concentration in proportion to the increase in fatigue, they can be evaluated as alternative indicators of mental fatigue. That is, in Examples 1 to 6 of the present invention, also in the effect of preventing mental fatigue. It turns out that it has a high effect. Further, it can be seen that this tendency appears more remarkably in Examples 5 and 6.
産業上の利用可能性 Industrial applicability
上記のように、本発明によるアミノ酸糸且成物を含んでなる疲労防止剤は、筋肉疲労 と精神疲労との双方を同時に防止するという、高い疲労防止効果を提供することが出 来る。また、従来のような運動能力などの向上を目的とするアミノ酸組成物と比較して 、より少ない種類のアミノ酸種類カゝらなる組成物であるため、調製に必要な原材料種 が減り、工業的にも経済的にも優れた効果を奏する。したがって、産業上の利用価値 は高いものである。  As described above, the anti-fatigue agent comprising the amino acid yarn according to the present invention can provide a high anti-fatigue effect that simultaneously prevents both muscular fatigue and mental fatigue. In addition, compared to conventional amino acid compositions aimed at improving athletic ability and the like, it is a composition consisting of fewer types of amino acids, so that the number of raw material types required for preparation is reduced and industrial production is reduced. In addition, it has an excellent economic effect. Therefore, the industrial utility value is high.

Claims

請求の範囲 The scope of the claims
[1] 以下のアミノ酸力 なるアミノ酸組成物を含む疲労防止剤：  [1] An anti-fatigue agent comprising an amino acid composition having the following amino acid strength:
プロリン 30〜200重量部；  30 to 200 parts by weight of proline;
グリシン 60〜140重量部；  60-140 parts by weight of glycine;
ァラニン 25〜260重量言  Alanin 25-260 weight
リジン 40〜130重量部；  40-130 parts by weight of lysine;
トリプトファン 20〜75重量部；  Tryptophan 20-75 parts by weight;
ヒスチジン 15〜40重量部。  Histidine 15-40 parts by weight.
[2] さらに、以下のアミノ酸を含有する請求項 1に記載の疲労防止剤：  [2] The anti-fatigue agent according to claim 1, further comprising the following amino acid:
スレオ-ン 35〜65重量部；  35-65 parts by weight of threon;
チロシン 15〜65重量部；  Tyrosine 15-65 parts by weight;
アルギニン 25〜45重量部。  Arginine 25-45 parts by weight.
[3] さらに、以下のアミノ酸を含有する請求項 1又は 2に記載の疲労防止剤：  [3] The fatigue inhibitor according to claim 1 or 2, further comprising the following amino acids:
ノ リン 30〜55重量部；  Norin 30-55 parts by weight;
ロイシン 35〜60重量部；  35-60 parts by weight of leucine;
イソロイシン 25〜45重量部。  25 to 45 parts by weight of isoleucine.
[4] 筋肉疲労および神経疲労の双方を同時に防止する、請求項 1〜3のいずれかに記 載の疲労防止剤。 [4] The fatigue inhibitor according to any one of claims 1 to 3, which simultaneously prevents both muscle fatigue and nerve fatigue.
[5] 筋肉疲労が行動量測定によって評価されるものであり、神経疲労が血中バイオマ 一力一測定によって評価されるものである、請求項 4に記載の疲労防止剤。  [5] The anti-fatigue agent according to claim 4, wherein muscular fatigue is evaluated by measuring the amount of behavior, and nerve fatigue is evaluated by measuring blood biomia.
[6] 行動量測定による評価において、非投与群の行動量を 100とした場合に投与群の 行動量 (相対値）が 110以上であり、かつ、血中バイオマーカー測定による評価にお いて、非投与群の測定濃度を 100とした場合に投与群の測定濃度湘対値)が 96以 下であり、筋肉疲労および神経疲労の防止効果を有すると評価される、請求項 5〖こ 記載の疲労防止剤。  [6] In the evaluation by the behavioral amount measurement, when the behavioral amount of the non-administration group is 100, the behavioral amount (relative value) of the administration group is 110 or more, and in the evaluation by the blood biomarker measurement, The measured concentration of the non-administered group is 100 (the measured concentration of the administered group) is 96 or less, and is evaluated to have an effect of preventing muscle fatigue and nerve fatigue. Anti-fatigue agent.
PCT/JP2007/061879 2006-06-13 2007-06-13 Anti-fatigue agent containing amino acid composition WO2007145239A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008521230A JP5775657B2 (en) 2006-06-13 2007-06-13 Anti-fatigue agent containing amino acid composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-163683 2006-06-13
JP2006163683 2006-06-13

Publications (1)

Publication Number Publication Date
WO2007145239A1 true WO2007145239A1 (en) 2007-12-21

Family

ID=38831753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/061879 WO2007145239A1 (en) 2006-06-13 2007-06-13 Anti-fatigue agent containing amino acid composition

Country Status (4)

Country Link
JP (2) JP5775657B2 (en)
KR (1) KR20090019813A (en)
CN (1) CN101454000A (en)
WO (1) WO2007145239A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009057775A1 (en) * 2007-10-31 2009-05-07 Meiji Dairies Corporation Anti-fatigue agent comprising amino acid composition
WO2009104696A1 (en) * 2008-02-19 2009-08-27 株式会社アーネストメディスン Oral or enteral composition useful for recovery of physical functions
JPWO2010041647A1 (en) * 2008-10-06 2012-03-08 株式会社明治 Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition as an active ingredient
JP2013060406A (en) * 2011-09-15 2013-04-04 Kyowa Hakko Bio Co Ltd Oral agent for brain fatigue improvement
JPWO2012169600A1 (en) * 2011-06-07 2015-02-23 味の素株式会社 Amino acid composition
JP2015120715A (en) * 2006-06-13 2015-07-02 株式会社明治 Anti-fatigue agent containing amino acid composition
JP2016014007A (en) * 2014-06-13 2016-01-28 花王株式会社 Muscle protein synthesis signal activator
JP2016121194A (en) * 2016-04-05 2016-07-07 協和発酵バイオ株式会社 Oral agent for cerebral fatigue improvement
JPWO2015053337A1 (en) * 2013-10-09 2017-03-09 味の素株式会社 Food containing histidine and use thereof
EP3466434A4 (en) * 2016-05-26 2020-01-22 Profeat Biotechnology Co. Ltd. Use of composition comprising ferrous amino acid chelate for manufacture of medicine for reducing lactic acid
US11045437B2 (en) 2018-08-27 2021-06-29 Ajinomoto Co., Inc. Composition for improving brain function

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104509919A (en) * 2013-09-30 2015-04-15 张自力 Functional nutrient beverage
JP7266581B2 (en) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド Amino acid composition for treatment of liver disease
KR102235563B1 (en) 2020-08-26 2021-04-02 (주)이삼오구 Composition for fatigue recovery and sexual function improvement containing high content of arginine
JP7414676B2 (en) * 2020-09-14 2024-01-16 株式会社東芝 Load estimating device, method and program
JP7462127B1 (en) 2023-08-16 2024-04-05 株式会社Healthy Body Muscle Hypertrophy Composition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
JPH0725838A (en) * 1993-05-13 1995-01-27 Yotsuba Yuka Kk Orally administering agent for preventing or recovering fatigue
JP2518692B2 (en) * 1989-06-14 1996-07-24 理化学研究所 Muscle maintenance agent, nutrient tonic, infusion agent, nutritional supplement, fatigue recovery agent and lactic acid production regulator
JPH08198748A (en) * 1995-01-27 1996-08-06 Ajinomoto Co Inc Amino acid nutrient composition
JPH09249556A (en) * 1996-01-09 1997-09-22 Rikagaku Kenkyusho Amino acid composition
JP2001226272A (en) * 2000-02-18 2001-08-21 Zeria Pharmaceut Co Ltd Liquid medium for oral administration formulated with citric acid and royal jelly
WO2004028528A1 (en) * 2002-09-30 2004-04-08 Riken Amino acid compositions for improving central functions
JP2004352696A (en) * 2003-05-30 2004-12-16 Institute Of Physical & Chemical Research Amino acids composition and fluid replacement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4009682B2 (en) * 1993-05-28 2007-11-21 独立行政法人理化学研究所 Adrenaline and noradrenaline secretion promoting composition
JP4280310B2 (en) * 1995-08-10 2009-06-17 佐々木化学工業株式会社 Amino acid composition
JP2000009717A (en) * 1998-02-27 2000-01-14 Taisho Pharmaceut Co Ltd Evaluation method for nourishment and robustness effect
JP3838038B2 (en) * 2001-02-05 2006-10-25 株式会社豊田中央研究所 Psychosomatic state evaluation method, evaluation method of sensibility quality of goods or environment, measurement kit for evaluation and quality display method of goods or environment
JP2003207495A (en) * 2002-01-10 2003-07-25 Toyota Central Res & Dev Lab Inc Device for judging psychological state
JP4484058B2 (en) * 2002-10-11 2010-06-16 味の素株式会社 Fatigue recovery food composition
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
JP3923507B2 (en) * 2004-02-17 2007-06-06 株式会社総合医科学研究所 Fatigue level evaluation apparatus, fatigue level evaluation method and use thereof
JP2005239579A (en) * 2004-02-24 2005-09-08 Ajinomoto Co Inc Fatigue-recovering agent and fatigue-recovering food
CN101454000A (en) * 2006-06-13 2009-06-10 明治乳业株式会社 Anti-fatigue agent containing amino acid composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
JP2518692B2 (en) * 1989-06-14 1996-07-24 理化学研究所 Muscle maintenance agent, nutrient tonic, infusion agent, nutritional supplement, fatigue recovery agent and lactic acid production regulator
JPH0725838A (en) * 1993-05-13 1995-01-27 Yotsuba Yuka Kk Orally administering agent for preventing or recovering fatigue
JPH08198748A (en) * 1995-01-27 1996-08-06 Ajinomoto Co Inc Amino acid nutrient composition
JPH09249556A (en) * 1996-01-09 1997-09-22 Rikagaku Kenkyusho Amino acid composition
JP2001226272A (en) * 2000-02-18 2001-08-21 Zeria Pharmaceut Co Ltd Liquid medium for oral administration formulated with citric acid and royal jelly
WO2004028528A1 (en) * 2002-09-30 2004-04-08 Riken Amino acid compositions for improving central functions
JP2004352696A (en) * 2003-05-30 2004-12-16 Institute Of Physical & Chemical Research Amino acids composition and fluid replacement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBAYASHI H.: "Sports to Amino Acid Supplement.", SHOKU NO KAGAKU, no. 225, 1999, pages 88 - 93, XP003000462 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015120715A (en) * 2006-06-13 2015-07-02 株式会社明治 Anti-fatigue agent containing amino acid composition
WO2009057775A1 (en) * 2007-10-31 2009-05-07 Meiji Dairies Corporation Anti-fatigue agent comprising amino acid composition
AU2008319747B2 (en) * 2007-10-31 2013-04-18 Meiji Co., Ltd. Anti-fatigue agent comprising amino acid composition
JP2014129394A (en) * 2007-10-31 2014-07-10 Meiji Co Ltd Anti-fatigue agent comprising amino acid composition
WO2009104696A1 (en) * 2008-02-19 2009-08-27 株式会社アーネストメディスン Oral or enteral composition useful for recovery of physical functions
US8778410B2 (en) 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
JPWO2010041647A1 (en) * 2008-10-06 2012-03-08 株式会社明治 Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition as an active ingredient
JPWO2012169600A1 (en) * 2011-06-07 2015-02-23 味の素株式会社 Amino acid composition
JP2013060406A (en) * 2011-09-15 2013-04-04 Kyowa Hakko Bio Co Ltd Oral agent for brain fatigue improvement
JPWO2015053337A1 (en) * 2013-10-09 2017-03-09 味の素株式会社 Food containing histidine and use thereof
JP2016014007A (en) * 2014-06-13 2016-01-28 花王株式会社 Muscle protein synthesis signal activator
JP2016121194A (en) * 2016-04-05 2016-07-07 協和発酵バイオ株式会社 Oral agent for cerebral fatigue improvement
EP3466434A4 (en) * 2016-05-26 2020-01-22 Profeat Biotechnology Co. Ltd. Use of composition comprising ferrous amino acid chelate for manufacture of medicine for reducing lactic acid
US11045437B2 (en) 2018-08-27 2021-06-29 Ajinomoto Co., Inc. Composition for improving brain function

Also Published As

Publication number Publication date
JP5775657B2 (en) 2015-09-09
CN101454000A (en) 2009-06-10
JP2015120715A (en) 2015-07-02
JPWO2007145239A1 (en) 2009-11-05
KR20090019813A (en) 2009-02-25

Similar Documents

Publication Publication Date Title
JP5775657B2 (en) Anti-fatigue agent containing amino acid composition
JP5798648B2 (en) Anti-fatigue agent containing amino acid composition
JP5574561B2 (en) Total enteral nutrition composition
US20210275582A1 (en) Composition of nutrition supplementation for nutritional deficiencies and method of use therefore
AU2012299126B2 (en) Compositions and methods for use in promoting lean body mass
CA3140227A1 (en) Compositions and methods using a combination of calcium and at least one of oleuropein or metabolite thereof
HUE032597T2 (en) Nutritional composition for the stimulation of muscle protein synthesis
JP6948103B2 (en) Frailty improvement combination
JP2019099498A (en) Composition for promoting lipid metabolism
JP2016102064A (en) Lipid metabolism accelerating agent
Komorowski et al. Inositol-Stabilized Arginine Silicate: A Novel Nitric Oxide-Boosting Ingredient for Sports Nutrition and Improved Cognition
JP2016094466A (en) Motor function improver
JP2023530485A (en) Compositions and uses of β-hydroxy-β-methylbutyrate (HMB) to improve muscle mass, strength and muscle function without exercise
JP2019099495A (en) Composition for promoting blood pressure fall
JP2019099497A (en) Composition for improving liver function
JP2019058140A (en) Nutritional composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780019510.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07767105

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020087029275

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008521230

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07767105

Country of ref document: EP

Kind code of ref document: A1